ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

Rhea-AI Summary

ALX Oncology announced its participation in the Jefferies Global Healthcare Conference. The event will take place on June 5, 2024, at 1:00 PM ET in New York, NY. The company, focused on developing therapies to block the CD47 immune checkpoint pathway, will engage in a fireside chat with analyst Michael Yee and hold one-on-one investor meetings. A live webcast of the chat will be accessible via the Investors section of ALX Oncology's website, with a replay available for 90 days.

Positive

• ALX Oncology's participation in a prestigious healthcare conference can increase visibility and investor interest.
• Fireside chat format with analyst Michael Yee may provide valuable insights into ALX Oncology's strategies and developments.
• One-on-one meetings with investors could foster strategic partnerships and attract funding opportunities.
• The event's webcast allows wider access to the company's presentation, increasing transparency and engagement.

Negative

• The announcement lacks specific updates on clinical progress or financial performance, which might be a concern for investors seeking concrete data.
• No new product launches or major breakthroughs were mentioned, leading to potential disappointment among stakeholders expecting significant news.
• The reliance on webcast replays may limit immediate impact as live engagement often drives more robust investor interactions.

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in the Jefferies Global Healthcare Conference. Details are as follows:

Format: Fireside chat with analyst, Michael Yee and 1x1 Investor Meetings
Date: Wednesday, June 5, 2024
Time: 1:00 PM ET
Location: New York, NY
Webcast link: Available here

The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website at Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. To date, evorpacept has been dosed in over 500 subjects and has demonstrated promising activity and favorable tolerability profile across a range of hematologic and solid malignancies in combination with various leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors.

FAQ

When is ALX Oncology participating in the Jefferies Global Healthcare Conference?

ALX Oncology will participate on June 5, 2024, at 1:00 PM ET.

Where is the Jefferies Global Healthcare Conference held?

The conference is held in New York, NY.

What format will ALX Oncology's participation take at the Jefferies Global Healthcare Conference?

ALX Oncology will participate in a fireside chat with analyst Michael Yee and hold one-on-one investor meetings.

How can I access the live webcast of ALX Oncology's fireside chat?

The live webcast can be accessed through the Investors section of ALX Oncology's website under the News and Events tab.

How long will the replay of the Jefferies fireside chat be available?

The replay will be archived for up to 90 days following the fireside chat date.